Reported Financial Results, Acquisitions, Conference Call Schedule, and Dividend Authorizations - Analyst Notes on Henry Schein, MWI Veterinary, Patterson, Prestige and Owens & Minor

NEW YORK, May 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Henry Schein, Inc. (NASDAQ: HSIC), MWI Veterinary Supply, Inc. (NASDAQ: MWIV), Patterson Companies Inc. (NASDAQ: PDCO), Prestige Brands Holdings, Inc. (NYSE: PBH) and Owens & Minor Inc. (NYSE: OMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2596-100free.

--
Henry Schein, Inc. Analyst Notes
On May 6, 2014, Henry Schein, Inc. (Henry Schein) reported its Q1 FY 2014 (period ended March 29, 2014) financial results with net sales of $2.4 billion, up 6.0% YoY. Net income attributable to Henry Schein was $102.1 million, or $1.18 per diluted share, up 11.6% or 14.6% YoY, respectively. "We are pleased to begin 2014 with solid first quarter financial results despite severe winter weather throughout many parts of the U.S.," said Stanley M. Bergman, Chairman of the Board and CEO of Henry Schein. "While we believe our U.S. sales in each of our business groups were adversely impacted by weather, we are pleased with our first quarter EPS performance and to be affirming our 2014 financial guidance." For FY 2014, the Company expects diluted EPS attributable to Henry Schein to be between $5.29 and $5.39, which represents growth of 7% - 9% YoY. The full analyst notes on Henry Schein are available to download free of charge at:

http://www.analystsreview.com/2596-HSIC-19May2014.pdf

--
MWI Veterinary Supply, Inc. Analyst Notes
On May 6, 2014, MWI Veterinary Supply, Inc. (MWI Veterinary) reported its Q2 FY 2014 financial results (period ending March 31, 2014). Total revenues were $721.3 million, up 28.1% YoY. Net income for the quarter was $16.8, up 11.1% YoY. Diluted EPS were $1.32 compared to $1.19 in Q2 FY 2013. "Our results for the quarter were impressive in spite of the severe winter weather conditions that impacted our operations and sales," said Jim Cleary, President and CEO of MWI Veterinary. "Our revenue growth was strong and we are very pleased with the tremendous progress our combined team has made towards integrating IVESCO." For FY 2014, the Company estimates revenues will be from $2.89 billion to $2.94 billion, which represents growth of 23% to 25% YoY and diluted EPS will be from $5.47 to $5.67 per share, which represents growth of 10.5% to 14.5% YoY. The full analyst notes on MWI Veterinary are available to download free of charge at:

http://www.analystsreview.com/2596-MWIV-19May2014.pdf

--
Patterson Companies Inc. Analyst Notes
On May 8, 2014, Patterson Companies Inc. (Patterson) announced that it will hold a conference call to discuss its Q4 FY 2014 financial results on May 22, 2014 at 9:00 a.m. ET. The Company informed that it will issue its financial results on the same day morning before the market opens. A live webcast of the conference call can be accessed by going to the investor relations section of Patterson's website. The full analyst notes on Patterson are available to download free of charge at:

http://www.analystsreview.com/2596-PDCO-19May2014.pdf

--
Prestige Brands Holdings, Inc. Analyst Notes
On April 25, 2014, Prestige Brands Holdings, Inc. (Prestige) announced that it has entered into a definitive agreement to acquire Insight Pharmaceuticals Corporation (Insight) for $750 million in cash. According to Prestige, Insight is a marketer and distributor of feminine care and other over-the-counter healthcare products. The Company informed that the acquisition will help extend Prestige's portfolio of iconic OTC brands to include Insight's leading feminine care platform anchored by Monistat®, the #1 brand in OTC yeast infection treatment. The aforesaid acquisition will also give the Company a leading platform in feminine care in the U.S. and Canada, while also adding other OTC brands to its cough/cold, pain relief, eye and ear, and dermatological platforms. The Company anticipates closing of the transaction during H1 2014. The full analyst notes on Prestige are available to download free of charge at:

http://www.analystsreview.com/2596-PBH-19May2014.pdf

--
Owens & Minor Inc. Analyst Notes
On April 30, 2014, the Board of Directors of Owens & Minor, Inc. (Owens & Minor) has authorized and declared a quarterly cash dividend in the amount of $0.25 per share. The cash dividend is payable on June 30, 2014, to shareholders of record as of June 16, 2014. The full analyst notes on Owens & Minor are available to download free of charge at:

http://www.analystsreview.com/2596-OMI-19May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review